We are live on
!
Find out more
HAG
HighPoint Advisor Group Portfolio holdings
AUM
$2.84B
1-Year Est. Return
31.94%
This Fund
S&P 500
This Quarter
Est. Return
+8.4%
1 Year Est. Return
+31.94%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$993M
AUM Growth
+$129M
(+15%)
Cap. Flow
+$92.7M
Cap. Flow
% of AUM
9.33%
Top 10 Holdings %
Top 10 Hldgs %
30.04%
Holding
594
New
70
Increased
355
Reduced
101
Closed
33
Avg Time Held
9
quarters
Top 10 Avg Time Held
7.3
quarters
Top 20 Avg Time Held
12.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$5.38M |
| 2 |
Apple
AAPL
|
+$4.64M |
| 3 |
JPMorgan Chase
JPM
|
+$4.48M |
| 4 |
Amazon
AMZN
|
+$3.83M |
| 5 |
FS KKR Capital
FSK
|
+$3.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sherwin-Williams
SHW
|
+$4.92M |
| 2 |
FSKR
FS KKR Capital Corp. II
FSKR
|
+$3.37M |
| 3 |
Tesla
TSLA
|
+$1.2M |
| 4 |
News Corp Class A
NWSA
|
+$944K |
| 5 |
NIO
NIO
|
+$835K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.84% |
| 2 | Financials | 14.16% |
| 3 | Healthcare | 13.02% |
| 4 | Consumer Discretionary | 12.37% |
| 5 | Communication Services | 9.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
501
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $195K | 0.02% |
16,853
-200
| -1% | -$2.32K |
2020 Q4
2 quarters
|
|
502
DELISTED
Advent Technologies
ADN
| $194K | 0.02% |
671
+36
| +6% | +$12K |
2020 Q4
2 quarters
|
|
|
ETRM
503
DELISTED
EnteroMedics Inc.
ETRM
| $185K | 0.02% |
+37,067
| New | +$185K |
2021 Q2
0 quarters
|
|
504
Huntington Bancshares
HBAN
$31B
| $183K | 0.02% |
+12,851
| New | +$197K |
2021 Q2
0 quarters
|
|
505
Takeda Pharmaceutical
TAK
$59.8B
| $183K | 0.02% |
10,844
-531
| -5% | -$9.04K |
2020 Q4
2 quarters
|
|
506
Compugen
CGEN
$202M
| $180K | 0.02% |
21,799
-10
| -0% | -$81 |
2021 Q1
1 quarter
|
|
507
Chimera Investment
CIM
$750M
| $180K | 0.02% |
3,980
+177
| +5% | +$7.36K |
2020 Q4
2 quarters
|
|
508
Cronos Group
CRON
$1.19B
| $170K | 0.02% |
19,731
-375
| -2% | -$3.1K |
2019 Q1
9 quarters
|
|
509
SiriusXM
SIRI
$8.94B
| $157K | 0.02% |
2,406
-194
| -7% | -$12.2K |
2018 Q2
12 quarters
|
|
|
ZNGA
510
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $131K | 0.01% |
12,309
-4,208
| -25% | -$44.3K |
2020 Q2
4 quarters
|
|
511
Ericsson
ERIC
$31.1B
| $129K | 0.01% |
+10,285
| New | +$138K |
2021 Q2
0 quarters
|
|
512
Lloyds Banking Group
LYG
$77.6B
| $121K | 0.01% |
47,416
-1,956
| -4% | -$5.02K |
2018 Q2
12 quarters
|
|
513
CareCloud
CCLD
$85M
| $118K | 0.01% |
13,975
-60
| -0.4% | -$498 |
2021 Q1
1 quarter
|
|
514
Banco Santander
SAN
$195B
| $103K | 0.01% |
26,373
-894
| -3% | -$3.47K |
2018 Q2
12 quarters
|
|
|
PRTK
515
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $100K | 0.01% |
14,679
-600
| -4% | -$4.85K |
2019 Q2
8 quarters
|
|
|
FEI
516
DELISTED
FIRST TRUST MLP AND ENERGY INCOME FUND
FEI
| $96K | 0.01% |
12,163
| – | – |
2020 Q4
2 quarters
|
|
517
MBody AI Ltd. Ordinary Share
MBAI
$49.7M
| $82K | 0.01% |
457
| – | – |
2020 Q4
2 quarters
|
|
518
ProQR Therapeutics
PRQR
$230M
| $67K | 0.01% |
+10,000
| New | +$64.5K |
2021 Q2
0 quarters
|
|
519
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $65K | 0.01% |
1,136
+67
| +6% | +$3.58K |
2020 Q1
5 quarters
|
|
520
DELISTED
Carisma Therapeutics
CARM
| $56K | 0.01% |
+610
| New | +$38.9K |
2021 Q2
0 quarters
|
|
521
Banco Bradesco
BBD
$45.5B
| $53K | 0.01% |
+11,427
| New | +$49.7K |
2021 Q2
0 quarters
|
|
522
iBio
IBIO
$56M
| $39K | ﹤0.01% |
52
| – | – |
2020 Q4
2 quarters
|
|
|
AMPE
523
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
| $38K | ﹤0.01% |
75
| – | – |
2019 Q2
8 quarters
|
|
524
Sundial Growers
SNDL
$300M
| $36K | ﹤0.01% |
3,804
+2,164
| +132% | +$19.8K |
2021 Q1
1 quarter
|
|
|
APTX
525
DELISTED
Aptinyx Inc. Common Stock
APTX
| $33K | ﹤0.01% |
11,791
| – | – |
2020 Q4
2 quarters
|
|
Similar funds
FMC
ORCP
PCIG
DIG
BDLIB
EMFAT
WGI
RL
HighPoint Advisor Group's Q2 2021 Portfolio in Review
As of Q2 2021, HighPoint Advisor Group held 594 positions worth $993M, up 15% from $864M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
HighPoint Advisor Group deployed $92.7M of net new capital in Q2 2021, opening 70 new positions and adding to 355 existing holdings. Its largest new stake was NRX Pharmaceuticals: 4,350 shares worth $505K.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 26% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Sherwin-Williams, an estimated $4.92M trimmed.
- HighPoint Advisor Group's largest Q2 2021 buy was NRX Pharmaceuticals: 4,350 shares worth $505K.
- HighPoint Advisor Group added most to Microsoft in Q2 2021, an estimated $5.38M increase.
- HighPoint Advisor Group's biggest Q2 2021 reduction was Sherwin-Williams, cutting an estimated $4.92M.
- HighPoint Advisor Group fully exited FS KKR Capital Corp. II in Q2 2021, selling an estimated $3.37M.
- HighPoint Advisor Group's ten largest holdings make up 30% of its $993M portfolio in Q2 2021.
- HighPoint Advisor Group opened 70 new positions and closed 33 in Q2 2021.
- HighPoint Advisor Group's portfolio value rose 15% quarter-over-quarter to $993M.
Based on HighPoint Advisor Group's 13F filing for Q2 2021, filed 29 Jul 2021.